We use cookies to ensure that our site works correctly and provides you with the best experience. If you continue using our site without changing your browser settings, we'll assume that you agree to our use of cookies. Find out more about the cookies we use and how to manage them by reading our cookies policy. Hide

Canada Medal

Canada

Established in 1939

The Canada Medal is awarded to a business leader for outstanding service in a Canadian industry, who has had a clearly positive impact on their business that is based on chemistry for its processes and/or services, a definition which includes not only traditional chemical companies focusing on chemical manufacture and distribution, but also industries such as bio-technology, coatings, crop protection, environmental services, fertilizer, food, mining/metal extraction, oil/gas, pharmaceuticals, plastics, pulp & paper and synthetic fibres.

Eligibility: Generally recipients will be business leaders in a Canadian industry, who have had a clearly positive impact on their business and on the Canadian industry as a whole. The career focus will likely be on economic and/or market leadership, but could include positive impacts on sustainability via social and/or environmental leadership.

Membership of SCI is not a prerequisite for receiving this award.

All nominations will remain in force for three years. Nominators are responsible for keeping the record of the nominee up to date and complete.

Description of Award: A plaque

Presented at: The award shall normally be presented at the annual SCI Canada Awards Dinner, typically held in early April, where the winner will be expected to attend and deliver a short acceptance speech. The winner may be invited to present a lecture at this event.

Frequency: Annual

Nomination Deadline: 30 September

Sponsor: SCI Canada

The 2017 winner of the Canada Medal is:

Mark Lievonen
Sanofi Pasteur Limited

Mark Lievonen is President of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi, which he joined in 1983. Under his leadership, Sanofi Pasteur has become a billion-dollar enterprise in Canada, manufacturing over 50 million doses of vaccines for both domestic and international markets.

A veteran of the industry for over 30 years, Lievonen began his career in finance and rose through Sanofi Pasteur’s ranks, guiding the company through a number of significant milestones and initiatives. He notably spearheaded a cancer vaccine program in 1997 and supported the key launch of a five-component pertussis vaccine, which is still widely used today. Working closely with the provincial and federal governments, Lievonen has led the site through several major contracts and investments, including the opening of the $100-million, state-of-the-art research and development facility in Toronto.

Lievonen holds a BBA in accounting and an MBA in finance and marketing from the Schulich School of Business, York University. He is a chartered accountant and received his designation while working with PricewaterhouseCoopers.

He is the recipient of many awards including a Queen’s Golden Jubilee Medallion, the Queen’s Diamond Jubilee Medal and was named a Member of the Order of Canada, in recognition of his outstanding achievements, leadership and unwavering commitment to the pursuit of sustainable healthcare.

Related Links

Share this article